| Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia Cancer Genome Atlas Research Network New England Journal of Medicine 368 (22), 2059-2074, 2013 | 4907 | 2013 |
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate PS Ward, J Patel, DR Wise, O Abdel-Wahab, BD Bennett, HA Coller, ... Cancer cell 17 (3), 225-234, 2010 | 2383 | 2010 |
| The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells LP Vu, BF Pickering, Y Cheng, S Zaccara, D Nguyen, G Minuesa, T Chou, ... Nature medicine 23 (11), 1369-1376, 2017 | 1108 | 2017 |
| Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism T Farge, E Saland, F De Toni, N Aroua, M Hosseini, R Perry, C Bosc, ... Cancer discovery 7 (7), 716-735, 2017 | 781 | 2017 |
| CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins M Carroll, S Ohno-Jones, S Tamura, E Buchdunger, J Zimmermann, ... Blood, The Journal of the American Society of Hematology 90 (12), 4947-4952, 1997 | 747 | 1997 |
| ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression O Abdel-Wahab, M Adli, LM LaFave, J Gao, T Hricik, AH Shih, S Pandey, ... Cancer cell 22 (2), 180-193, 2012 | 709 | 2012 |
| Survival of acute myeloid leukemia cells requires PI3 kinase activation Q Xu, SE Simpson, TJ Scialla, A Bagg, M Carroll Blood 102 (3), 972-980, 2003 | 624 | 2003 |
| Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ... Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014 | 534 | 2014 |
| An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells ML Guzman, RM Rossi, S Neelakantan, X Li, CA Corbett, DC Hassane, ... Blood, The Journal of the American Society of Hematology 110 (13), 4427-4435, 2007 | 523 | 2007 |
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, ... Leukemia 29 (8), 1637-1647, 2015 | 481 | 2015 |
| Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice JE Sarry, K Murphy, R Perry, PV Sanchez, A Secreto, C Keefer, ... The Journal of clinical investigation 121 (1), 384-395, 2011 | 477 | 2011 |
| AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3 M Wunderlich, FS Chou, KA Link, B Mizukawa, RL Perry, M Carroll, ... Leukemia 24 (10), 1785-1788, 2010 | 468 | 2010 |
| Single-cell mutation analysis of clonal evolution in myeloid malignancies LA Miles, RL Bowman, TR Merlinsky, IS Csete, AT Ooi, ... Nature 587 (7834), 477-482, 2020 | 406 | 2020 |
| Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia S Li, FE Garrett-Bakelman, SS Chung, MA Sanders, T Hricik, F Rapaport, ... Nature medicine 22 (7), 792-799, 2016 | 402 | 2016 |
| Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia CM McMahon, T Ferng, J Canaani, ES Wang, JJD Morrissette, ... Cancer discovery 9 (8), 1050-1063, 2019 | 394 | 2019 |
| Distinct IL-2 receptor signaling pattern in CD4+ CD25+ regulatory T cells SJ Bensinger, PT Walsh, J Zhang, M Carroll, R Parsons, JC Rathmell, ... The Journal of Immunology 172 (9), 5287-5296, 2004 | 379 | 2004 |
| The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase … M Carroll, MH Tomasson, GF Barker, TR Golub, DG Gilliland Proceedings of the National Academy of Sciences 93 (25), 14845-14850, 1996 | 350 | 1996 |
| Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR SM Ranuncolo, JM Polo, J Dierov, M Singer, T Kuo, J Greally, R Green, ... Nature immunology 8 (7), 705-714, 2007 | 347 | 2007 |
| DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies AP Im, AR Sehgal, MP Carroll, BD Smith, A Tefferi, DE Johnson, ... Leukemia 28 (9), 1774-1783, 2014 | 322 | 2014 |
| Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders EO Hexner, C Serdikoff, M Jan, CR Swider, C Robinson, S Yang, ... Blood, The Journal of the American Society of Hematology 111 (12), 5663-5671, 2008 | 314 | 2008 |
Stephan A. GruppProfessor of Pediatrics, University of Pennsylvania School of MedicineVerified email at chop.edu
